$27.25
-0.87%BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Chairman of Scientific Advisory Board, Executive Vice President & Chief Scientific Officer
Compensation
$621,983
Chief Commercial Officer
Compensation
$496,635
Chief Executive Officer & Chairman
Compensation
$1,474,331
Chief Financial Officer
Compensation
$733,564
Chief Human Resources Officer
Chief Quality & Operations Officer
Compensation
$613,929
Chief Technology Officer
During the last 12 months, insiders have sold $104.47M worth of BLFS shares, with no buying activity reported.
0
0.00
1.2M
28.18M
-28.2M
-$28.18M
0
0.00
106.9K
2.19M
-2.2M
-$2.19M
0
0.00
937.7K
26.32M
-26.3M
-$26.32M
0
0.00
2.0M
47.77M
-47.8M
-$47.77M
No buying activity
Casdin Partners Master Fund, L.P.
10 Percent Owner
$96.84M
De Greef Roderick
Director, Officer: President And Ceo
$3.61M
Foster Karen A.
Officer: Chief Quality And Operations
$2.11M
Wichterman Troy
Officer: Chief Financial Officer
$960K
Berard Todd
Officer: Chief Marketing Officer
$332K
Strong bearish signal with $104.47M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
BLFS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | July 08, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 05, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | June 06, 2023 | June 06, 2023 | ย | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 18, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | May 29, 2020 | July 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 12, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 06, 2018 | May 18, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 14, 2017 | May 25, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | March 30, 2016 | May 10, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.